Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Dr Shelley Zieroth (University of Manitoba, CA), Prof Hiddo L Heerspink (University Medical Center, Groningen, NL) and Prof Kamlesh Khunti (University of Leicester, UK) discuss the implications for practice.

This three-part series, 'SGLT-2 Inhibitors and Cardio-renal Outcomes: Translating the Data into Practice', brings together three experts to review the implications for pathophysiology, screening and treatment strategies.

This programme is supported by an unrestricted educational grant from AstraZeneca